Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
The Oncologist
|
October 6, 2025
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey
Enrique Grande, Joaquim Bellmunt, Syed A Hussain, et al.
The New England Journal of Medicine
|
March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
The Oncologist
|
October 6, 2025
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey
Enrique Grande, Joaquim Bellmunt, Syed A Hussain, et al.
The New England Journal of Medicine
|
March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Page
of 8